ENANTA PHARMACEUTICALS, INC (ENTA) Net margin 2017–2025
ENANTA PHARMACEUTICALS, INC (ENTA) net profit margin by fiscal year — reported net income divided by reported revenue.
-177.6%FY2025 · since FY2017: 21.1% → -177.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -177.6% | +20.2 pp |
| FY2024 | -197.9% | -44.1 pp |
| FY2023 | -153.7% | -62.0 pp |
| FY2022 | -91.7% | -54.4 pp |
| FY2021 | -37.3% | -75.1 pp |
| FY2020 | 37.9% | +2.8 pp |
| FY2019 | 35.1% | +26.5 pp |
| FY2018 | 8.6% | -12.5 pp |
| FY2017 | 21.1% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More ENTA financial trends
ENTA RevenueENTA Net incomeENTA Gross profitENTA Gross marginENTA Operating incomeENTA Operating marginENTA Operating cash flowENTA Free cash flowENTA Capital expendituresENTA Return on equityENTA Stock buybacksENTA Dividends paidENTA Total assetsENTA Total liabilitiesENTA Shareholders’ equityENTA overview →